Reirradiation to previously irradiated peripheral bone metastases for pain has been shown to be safe and effective, but no specific trial has been completed to define the indications for reirradiation of patients with recurrent symptoms of metastatic bone disease. Thus, we aimed to assess the effectiveness and prognostic factors of reirradiation for painful bone metastases. To do so, we reviewed the cases of 14 patients with painful bone metastases who had undergone reirradiation at our hospital. A favorable pain response after reirradiation was achieved in 50% (7/14) of the patients. An interval from initial radiotherapy > 6 months was a significant prognostic factor for pain response (p = 0.03). Performance status was correlated with pain response, with borderline significance (p = 0.06). No severe adverse events were reported. We conclude that reirradiation of painful bone metastases is effective in providing pain relief, especially for patients with a long interval from initial radiation and good performance status.
INTRODUCTION
Pain relief from metastatic bone tumors comprises a considerable proportion of the work undertaken in departments of radiation oncology. Prior published data from many studies indicate overall pain response rates of 60%-90% [1] [2] [3] . In recent years, as a result of progress in anticancer therapy, survival of patients with distant metastatic disease is increasing. Reirradiation might be an option to palliate pain in patients who have had no pain relief after previously receiving radiation therapy, as well as in those who have had partial improvement in pain and who might receive additional benefit from repeat treatment, or in those whose pain has recurred after an initial satisfactory response [4] . The evidence for the safety and efficacy of reirradiation to previously irradiated areas of peripheral bone metastases for pain was derived from both prospective studies and retrospective data [2, [5] [6] [7] ]. In the systematic review by Wong et al., the complete response and partial response rates after reirradiation were 20% and 50%, respectively, and the overall pain response rate was 68% [7] . However, no specific trial has been completed to define the indications for reirradiation of patients with recurrent symptoms of metastatic bone disease. The aim of this study was to assess the effectiveness and prognostic factors of reirradiation for painful bone metastases. A review of the literature was also undertaken, the results of which are compared with the current study, focusing on the pain response rate and prognostic factors for pain relief.
MATERIALS AND METHODS
Between January 2010 and December 2015, we retrospectively analyzed 14 patients who underwent reirradiation for painful bone metastases at our institution. Reirradiation was performed on the same location as the initial irradiation. We defined reirradiation as radiotherapy performed at least 1 month after the end of the initial local irradiation. All patients received threedimensional planning for both initial irradiation and reirradiation. The patients were informed of the risk of reirradiation, especially the risk of radiation-induced myelopathy, and written informed consent was obtained before treatment. Patient's characteristics are summarized in Table 1 . The 11 men and 3 women had a median age of 76 years (range, 23 to 89 years). The Eastern Cooperative Oncology Group performance status (PS) of six patients (43%) was 0 or 1 at the time of reirradiation. The primary tumors included three in liver, three in prostate, two renal, and five other tumors. All patients except one had multiple bone metastases. The time interval between radiation episodes was defined as the time between the end of the initial radiation and the start of reirradiation. The most commonly used treatment regimen at initial radiation was 30 Gy in 10 fractions over 2 weeks. An additional dose in the range from 5 Gy in 1 fraction to 30 Gy in 10 fractions was administered. The fractionated schemas were determined according to the condition of the patient, the site of reirradiation, and the discretion of the radiation oncologists. Overlapping sites of the initial radiation and the reirradiation were the pelvic bone in six patients, thoracic spine in three patients, long bone in two patients, lumbar spine in one patient, shoulder in one patient, and rib in one patient. The treatment characteristics are summarized in Table 2 .
The biologically effective dose (BED) was calculated to assess the cumulative radiation dose from the initial radiation and the reirradiation, because the frac- 6 
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tionation schemas used for the initial radiation and the reirradiation were different. The BED was calculated by the equation BED = D × (1 + d/α/β), as derived from the linear-quadratic model, where D = total dose and d = dose per fraction. We adopted 10 Gy as the α/β ratio for acute toxicities and 2 Gy for the toxicities.
The criteria for subjective response were as follows: CR was defined as complete disappearance of pain; PR was defined as ~50% improvement in pain; no response (NR) was defined as minimal (<50%) or no improvement in pain. Twelve patients showed some type of pain response at initial radiation: six had a CR and six had a PR. The remaining two patients did not respond to the initial radiation.
Acute and late adverse events after reirradiation were scored according to the Common Terminology Criteria of Adverse Events, version 4.0 [8] . Acute adverse events were defined as those arising less than 4 weeks after the first day of reirradiation. The presence of pathological fracture and spinal cord compression or cauda equina syndrome within the field was assessed by the individual treating physicians. Overall survival (OS) was defined as the time from the end of reirradiation to the date of death or last follow-up. We obtained approval for this retrospective study from the Ethics Committee of Kyoto prefectural university of medi-cine (ERB-C-872).
Statistical analysis
All statistical analyses were performed with Statview 5.0 statistical software (SAS Institute, Cary, NC, USA). Survival data were estimated by the Kaplan-Meier method. Prognostic factors were examined for significance by the chi-square test. All analyses used the conventional p < 0.05 level to determine statistical significance.
RESULTS
The median follow-up period was 4 months (range, 1-12 months) for all eligible patients. At the time of the last follow-up, 3 (23%) patients were alive and 10 (67%) patients had died. The median interval from initial radiation to reirradiation was 8 months (range, 1-48 months). The median BED for initial radiation and reirradiation was 75 Gy 2 (range, 40-112.5 Gy 2 , α/β = 2) and 60 Gy 2 (range, 12-75 Gy 2 , α/β = 2), respectively. The median cumulative BED from initial radiation and reirradiation was 137 Gy 2 (range, 80-215 Gy 2 , α/β = 2). Table 3 shows the treatments and clinical outcomes for individual patients. A pain response (CR or PR) after reirradiation was achieved in 50% (7/14) of patients: one (7%) had a CR and 6 (43%) had Overall survival curve after reirradiation according to response. The difference between the responder and nonresponder groups was significant (p = 0.003).
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a PR. The remaining 7 (50%) did not benefit from reirradiation. The median duration of pain relief in responders was 5 months. Table 4 summarizes the prognostic factors considered to be associated with pain response. In this analysis, the interval from initial radiotherapy (>6 months) was found to be significant (p = 0.03). PS 3 was found to be an important prognostic factor that prevented pain relief; however, the relation was not statistically significant (p = 0.06). OS curves after reirradiation are shown in Fig. 1 . The median survival time (MST) after reirradiation was 4 months (range, 1-12 months). Responders had significantly better OS after reirradiation than did nonresponders (p = 0.003) (Fig. 2) . Two patients had grade 1 or 2 nausea and vomiting. There were no acute adverse events of grade > _ 3.
One patient had cauda equina compression. At the time of analysis, no cases of radiation-induced myelopathy were reported.
DISCUSSION
The purpose of this study was to examine the effectiveness of reirradiation on painful bone metastases in patients who had previously received radiation at the same site. The overall response rate was 50% (7/14), and CR was achieved in only one patient (7%). The pain response outcomes in previous studies [5, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] are shown in Table 5 . The CR rates for reirradiation ranged from 11% to 100%, and the PR rates ranged from 31% to 78%. Different definitions of pain relief end points were used in different studies, introducing a potential source of bias. In the systematic review by Wong et al., the CR and PR rates after reirradiation were 20% and 50%, respectively, and the overall response rate was 68% [7] . To our knowledge, there have been only a few reports on the prognostic factors for pain response (Table 5 ). Hayashi et al. concluded that PS at reirradiation and the time from initial treatment to reirradiation were associated with pain relief. They reported that reirradiation was most useful in patients with a single area of bone metastasis, a high PS,
and an interval from initial radiation > _ 4 months [13] .
In our study, PS at the time of reirradiation was a borderline significant prognostic factor for pain response, and 8 of 14 patients (57%) were PS > _ 2. All patients except one had multiple bone metastases. These patients' characteristics may be among the reasons for their poorer clinical outcome compared with previous
reports. An interval from initial radiation > 6 months was found to be an important factor associated with reirradiation response in our study. Patients with a short interval from initial radiation might have aggressive disease, and for such patients palliative radiation therapy is generally considered less effective. A recent multicenter, phase III randomized trial of reirradiation for painful bone metastases [4] , using intention-to-treat analysis, found that a single fraction of 8 Gy was noninferior to a multiple fractionated retreatment schedule of 20 Gy, with similar response rates for the two schedules, 28% and 32%, respectively. In this report, no difference in pain response was noted between groups when the per-protocol population was analyzed by the interval from initial radiation to randomization (> 3 months vs. < _ 3 months) [5] .
In the current study, two patients who did not respond to initial radiation also did not respond to reirradiation, although the initial response was not a significant prognostic factor for pain response. Hayashi et al. reported that initial nonresponders did not respond to reirradiation [13] , which agrees well with our results. On the other hand, van der Linden reported that 62% (33/53) of patients who did not respond to initial radiation responded to reirradiation [12] . Similarly, no differences in the pain response to reirradiation in relation to the overall pain response to initial radiation were reported in the NCIC CTG SC 20 trial [4] . Jeremic et al. reported that 12 of 26 initial nonresponders (46%) responded to reirradiation, and that patients with a previous CR were more likely to achieve a CR than were patients with a previous PR [15] . In our study, only one of six patients with a previous CR achieved a CR with reirradiation (Table 3 ). It is difficult to determine a true benefit of palliative reirradiation in our study because of the retrospective nature of the data collection and the lack of a standardized pain outcome tool.
Our study found an MST of 4 months after reirradiation for the entire series, and there was a difference in survival between responders and nonresponders to reirradiation. Hernanz et al. found that the MST after reirradiation for symptomatic bone metastases was 3 months [10] . Similarly, Hayashi et al. found an MST of 4 months after reirradiation [13] , and reported that patients who responded to reirradiation survived significantly longer than patients who did not respond. The clinical outcomes of the patients in our study were consistent with their reports [13] . However, it cannot be concluded that successful treatment of painful bone metastases prolonged the life of these patients, because responders in our study were more likely to have good PS ( Table 3 ). Patients with good PS generally have a favorable prognosis.
Toxicities after reirradiation have not been consistently reported in the published studies. Two patients in our study (14%) had mild acute gastrointestinal toxicities, consisting of nausea and vomiting, and one patient had cauda equina compression. In the NCIC CTG SC 20 trial [4] , spinal cord or cauda equina compression was reported in 7 (2%) of 425 patients assigned to 8 Gy and 2 (< 1%) of 425 assigned to 20 Gy in an intention-to-treat population. Jeremic et al. reported spinal cord compression in 2.2% of patients undergoing reirradiation, grade 1 or 2 nausea and vomiting in 18.5%, and grade 1 or 2 diarrhea in 11.9%. No grade 3 or 4 toxicity was reported [15] . No cases of radiation-induced myelopathy were reported in this trial [15] . In the study by van der Linden et al., most patients had no or mild nausea and vomiting. Severe nausea occurred in three patients, and one patient had a severely painful skin reaction [12] . Roszkowski et al. reported the occurrence of nausea, vomiting, erythema of the skin, diarrhea, fever, fatigue, granulocytopenia, erythrocytopenia, and Lhermitte's sign in 15.8%, 3.5%, 40.4%, 1.8%, 7.0%, 24.6%, 8.8%, 10.5%, and 1.8% of patients, respectively. They also reported no serious complications [11] . Similarly, other published studies did not report any spinal cord compression or toxicity exceeding grade 3, although there were several mild toxicities [10] [11] [12] [13] . The evidence for the safety of reirradiation of painful bone metastases was derived from both prospective studies and retrospective data, and the treatment has been shown to be safe. For patients with persistent severe pain and unbearable side effects despite high doses of opioids and other analgesics after initial radiotherapy, we believe reirradia-
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tion should be considered. However, the indication should be limited to cases where the previous radiotherapy did not cause serious toxicity.
The limitations of our study are the small number of patients, the retrospective nature of the data collection, and the short follow-up period. In the future, it is recommended that patients be included in prospective randomized trials to further define the appropriate use of reirradiation in the setting of recurrent cancer symptoms.
In conclusion, patients with a long interval from initial radiation and good PS are appropriate candidates for reirradiation for painful bone metastases.
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